Avacopan (CCX168), a C5a receptor (C5aR) inhibitor, also recently showed excellent and safe preliminary outcomes in replacing high-dose glucocorticoids in AAV patients in a randomized, placebo-controlled trial [19]. The gene discussed is C5AR1; the disease is anti-neutrophil cytoplasmic antibody-associated vasculitis.